Spago Nanomedical AB

Spago Nanomedical's 177Lu-SN201 Shows Continued Safety in Phase I/IIa Trial Across Multiple Solid Tumors

- Spago Nanomedical's independent Data Monitoring Committee recommends continuing the Tumorad-01 phase I/IIa study with 177Lu-SN201, allowing recruitment of two additional patients at the current dose level. - The recommendation follows analysis of 14 patients with advanced solid tumors, demonstrating acceptable safety profile with maximum tolerated dose not yet reached. - SPECT/CT imaging confirmed visible tumor uptake of 177Lu-SN201 in treated patients, providing proof-of-concept for the drug's mechanism of action in humans. - The company is pursuing regulatory interactions to define the clinical development path forward, including potential orphan drug designation for the radiopharmaceutical candidate.